Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor.
Int J Oncol
; 22(6): 1271-6, 2003 Jun.
Article
em En
| MEDLINE
| ID: mdl-12738993
ABSTRACT
Arsenic compounds have been used to treat angiogenic diseases such as cancer, psoriasis, and rheumatoid arthritis in traditional oriental medicine. In recent years, arsenic trioxide (As2O3, diarsenic oxide) has been successfully used to treat acute promyelocytic leukemia. We investigated the antiangiogenic properties of tetraarsenic oxide (As4O6), another trivalent arsenic compound. In in vitro studies, tetraarsenic oxide inhibited the proliferation (IC50 = 99.7 nM), migration into the denuded area (IC50 = 27.4 nM), and invasion through a layer of Matrigel (IC50 = 73.5 nM) of basic fibroblast growth factor (bFGF)-stimulated bovine capillary endothelial (BCE) cells in a dose-dependent manner. Tetraarsenic oxide also inhibited the tube formation of human umbilical vein endothelial cells. Tetraarsenic oxide induced cell cycle arrest of bFGF-stimulated BCE cells in the G2/M phase and inhibited the secretion of matrix metalloproteinase-2 from BCE cells. Orally administered tetraarsenic oxide (50 mg/kg/day) inhibited bFGF-induced new-vessel formation in a rat corneal micropocket assay, and reduced by about 54% the number of experimental pulmonary metastatic nodules in mice implanted with B16F10 melanoma cells. Thus, we provide evidence that tetraarsenic oxide has effective antiangiogenic activities.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Arseniatos
/
Endotélio Vascular
/
Inibidores da Angiogênese
/
Neoplasias Pulmonares
/
Neovascularização Patológica
Idioma:
En
Revista:
Int J Oncol
Ano de publicação:
2003
Tipo de documento:
Article